Anaphylaxis treatment market to hit $9.33 billion by 2030

The global anaphylaxis treatment market is projected to grow from $6.59 billion in 2025 to $9.33 billion by 2030, driven by rising food allergies, wider epinephrine access and stronger emergency care awareness. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest through the forecast period.

Why it matters: - The market is expanding as allergic conditions are diagnosed more often and demand rises for fast, life-saving treatment. - Growth in epinephrine-based therapies, auto-injectable devices and broader pharmacy access is shaping how severe allergic reactions are treated. - Rising food allergy rates are increasing the need for rapid intervention in homes, schools, hospitals and pharmacies.

What happened: - The Business Research Company published its Anaphylaxis Treatment Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report values the anaphylaxis treatment market at $6.59 billion in 2025 and projects $7.05 billion in 2026, implying 7.0% annual growth. - The market is forecast to reach $9.33 billion by 2030, with a 7.2% CAGR over the forecast period. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to grow at the fastest pace during the forecast period.

The details: - Anaphylaxis treatment covers severe, potentially fatal allergic reactions triggered by foods, insect stings, medications or latex. - Immediate epinephrine administration is critical to reverse symptoms and stabilize patients. - Effective care also requires swift medical attention and supportive treatment to prevent complications. - The market’s earlier growth reflects better diagnosis of allergic conditions, established emergency protocols, wider availability of epinephrine therapies, expanding hospital pharmacy networks and greater awareness among healthcare professionals. - Future growth is expected to come from investment in innovative drug delivery technologies, patient-focused care, digital pharmacy platforms and rapid-onset medications. - The report expects broader use of auto-injectable epinephrine devices, multi-drug regimens, stronger focus on immediate intervention and wider retail and online distribution. - The report also points to improved access to treatment as a major trend. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The latest report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated visual analysis.

Between the lines: - Food allergy prevalence is a key demand signal for the sector because it expands the pool of patients at risk of emergency anaphylaxis. - The May 2024 finding from the UK Food Standards Agency that about 6% of UK adults, or roughly 2.4 million people, had clinically confirmed food allergies highlights the scale of the issue. - The shift toward retail, online and digital pharmacy channels suggests treatment access is becoming as important as drug development. - The market outlook points to a mix of product innovation and distribution expansion rather than a single dominant growth driver.

What's next: - The market is expected to keep growing as allergy incidence rises and health systems prioritize faster emergency response. - Adoption of auto-injectors and rapid-onset medicines is likely to deepen as access improves across retail and online channels. - Regional growth is likely to remain uneven, with North America continuing to lead and Asia-Pacific closing the gap fastest. - The report invites readers to download a free sample here.